Prostate cancer is a sly little operator. Give it one blocked escape route and it starts checking the walls for vents, windows, and suspiciously loose ceiling tiles. That is why this new study on B7-H3 feels so interesting: the researchers may have found a target that stays visible across a wide stretch of prostate cancer’s many costume changes, including the nastier late-stage versions that love to stop answering the phone when treatment calls.[1]
At the center of the story is androgen receptor signaling, which is basically one of prostate cancer’s favorite fuel lines. A lot of standard therapy works by cutting that line through androgen deprivation therapy, or ADT. The problem is that tumors adapt. They do not politely accept defeat. They improvise, mutate, and redecorate the place while nobody is looking.[5]
This paper asked a very practical question: if prostate cancer keeps changing which surface proteins it displays, is there one target that remains broadly present enough to be worth chasing anyway? After looking across a huge single-cell atlas and validating the findings in patient tissue, the answer that rose to the top was B7-H3, also called CD276.[1]
The Tumor’s Name Tag Refuses to Fall Off
Think of cancer-cell surface targets as nametags for highly untrustworthy party guests. Some are easy to spot at first, then disappear once treatment starts. That makes targeted therapy tricky. You show up with a carefully aimed drug and the target has already slipped into a fake mustache.
What the authors found is that B7-H3 was unusually consistent across the prostate cancer continuum - from hormone-sensitive disease to castration-resistant prostate cancer, and even into more treatment-resistant subtypes like neuroendocrine and double-negative disease.[1] In plain English: when the tumor keeps changing outfits, B7-H3 still tends to be standing there under the same bad fluorescent lighting.
That matters because treatment resistance in advanced prostate cancer is often a problem of heterogeneity. Different patients’ tumors vary. Different areas within the same tumor vary. The metastatic deposits can look like a family reunion where nobody admits they are related. A target with lower inter-patient and intra-tumor variation is therefore a big deal.[1]
A Very Odd Plot Twist With Hormones
Here the wildlife documentary gets especially good.
The androgen receptor, the usual ringleader in prostate cancer, appears to negatively regulate B7-H3 in this study.[1] That means when androgen signaling is active, B7-H3 can be held down. When androgen signaling is blocked, B7-H3 may become more available. In other words, the very treatment used to starve the cancer might also help hang a brighter lantern on one of its surface markers.
This is not coming out of nowhere. Earlier studies also suggested a relationship between B7-H3 and androgen biology, though the timing appears complicated and context-dependent, because biology enjoys making every clean diagram slightly dishonest.[2,4] One 2023 study found B7-H3 changed during ADT and disease progression, supporting the idea that pairing hormone therapy with B7-H3-directed treatment could make sense.[4]
So the headline is not just “here is a target.” It is “here is a target that may become especially useful in combination with the therapy patients already get.”
Why Combination Therapy Gets People Interested
The paper also proposes B7-H3 as a combinatorial target, with promising pairings such as TROP-2, NECTIN1, KLK2, and NECTIN4.[1] That is the oncology version of not trusting a single lock on the door.
Why bother with combinations? Because advanced prostate cancer has a nasty habit of dodging single-target attacks. If one marker fades, another may remain. If one cell population slips away, another may still be vulnerable. Researchers have been moving in this direction more broadly with antibody-drug conjugates and other targeted approaches in prostate cancer, precisely because the disease can be so annoyingly adaptable.[3,6]
B7-H3 is already on the radar beyond this paper. Reviews from the past few years describe it as one of the more promising immunotherapy and ADC targets in prostate cancer, especially because its expression tends to be higher in aggressive disease and lower in most normal tissues.[2,3] That is the dream, of course: hit the troublemaker, spare the neighborhood.
And this is not just lab-bench fan fiction. B7-H3-directed drugs are already in clinical development, and the space has picked up momentum, including a U.S. FDA Fast Track designation in June 2024 for the B7-H3 ADC BNT324/DB-1311 in advanced castration-resistant prostate cancer.[7] There is also an NCI-listed trial testing enoblituzumab before prostatectomy in high-risk localized disease.[8]
What This Could Mean in the Real World
If these findings hold up, the payoff is pretty straightforward. Doctors could have a target that remains useful across multiple stages of prostate cancer, including forms that often become harder to treat as they drift away from standard hormone sensitivity. Even better, B7-H3-based therapy might work with androgen blockade rather than waiting around awkwardly in the lobby while standard treatment does all the work.
That does not mean patients should assume a new universal fix is around the corner. Tissue expression is not the same as clinical benefit. A target can look terrific under the microscope and still disappoint once real tumors, real toxicity, and real human biology show up to ruin everyone’s neat slide deck.
Still, this study gives a strong reason to keep watching B7-H3. In the scrubland of advanced prostate cancer, where cells evolve like crafty little mammals learning to raid the campsite after dark, it is useful to find a feature that stays visible long enough to matter. And here we observe the tumor, caught for once with its nametag still on.
References
-
Sharma S, Mundhara N, Tekoglu E, et al. Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly-Expressed, Combinatorial Therapeutic Target. Clinical Cancer Research. 2026. doi:10.1158/1078-0432.CCR-26-0642. PubMed: https://pubmed.ncbi.nlm.nih.gov/42053993/
-
Guo C, Figueiredo I, Gurel B, et al. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. European Urology. 2023;83(3):224-238. doi:10.1016/j.eururo.2022.09.004. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC7617982/
-
Pulido R, López JI, Nunes-Xavier CE. B7-H3: a robust target for immunotherapy in prostate cancer. Trends in Cancer. 2024;10(7):584-587. doi:10.1016/j.trecan.2024.05.003
-
Kang N, Xue H, Lin YY, et al. Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer. Cancer Gene Therapy. 2023;30(10):1382-1389. doi:10.1038/s41417-023-00644-9. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC10581905/
-
Shi X, Day A, Bergom HE, et al. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. npj Precision Oncology. 2022;6:80. doi:10.1038/s41698-022-00323-2
-
Hong K, Elsheshtawy A, Le Blevec S, et al. Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review. Cancers (Basel). 2023;15(5):1499. doi:10.3390/cancers15051499. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC9983052/
-
BioNTech. BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer. June 20, 2024. https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2024/06/biontech-and-dualitybio-receive-fda-fast-track-designation.html
-
National Cancer Institute. Enoblituzumab before Radical Prostatectomy versus Radical Prostatectomy Alone for the Treatment of High-Risk Localized Prostate Cancer. Accessed May 10, 2026. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2024-09884
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.